AmWINS Group Inc.

11/19/2026 | Press release | Distributed by Public on 11/19/2026 07:07

Amwins Launches Exclusive Clinical Trials Insurance Product, Pre-Licensed in 115+ Countries

Amwins, the largest independent wholesale distributor of specialty insurance products in the U.S., today announced the launch of an exclusive Clinical Trials insurance solution within its Brokerage division.

Developed in partnership with a leading Lloyd's syndicate in the clinical trials market, the product is available exclusively through Amwins brokers and offers clinical trials indemnity, no-fault compensation and clinical testing liability, as well as public, products and professional liability and medical malpractice coverage. The solution is written on paper pre-licensed in more than 115 countries.

Clinical trials insurance is a regulatory requirement in most territories and is often the final hurdle before a study can begin, yet many carriers are not licensed everywhere trials take place.

"When carriers lack the necessary licensing in a trial's host countries, sponsors may need to secure separate local policies, adding cost and administrative complexity," said Tom Dillon, Executive Vice President and National Casualty Practice Leader at Amwins. "By combining pre-licensed Lloyd's paper with broad underwriting appetite and same-day turnaround, we've created a solution that gives retail agents a dependable, single-placement option for clinical trial clients operating internationally."

The product supports a broad range of clinical research exposures across all phases of study, including but not limited to:

  • Sponsor liability for first-in-man/Phase I through Phase IV research
  • Contract research organization (CRO) exposures
  • Investigator-led studies
  • University clinical trial programs

Coverage highlights include limits of $25 million and no class limitations, with same-day quoting and same-day issuance of certificates and policy documents.

To learn more, contact your Amwins broker.

AmWINS Group Inc. published this content on November 19, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 19, 2026 at 13:07 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]